Janux Therapeutics, Inc. (JANX) News
Filter JANX News Items
JANX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest JANX News From Around the Web
Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionSAN DIEGO, December 07, 2024--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters o |
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsSAN DIEGO, December 05, 2024--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purcha |
Why Janux Therapeutics Crushed the Market TodayNews of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (NASDAQ: JANX) stock on Wednesday. Well before market open, Scotiabank pundit George Farmer aggressively raised his price target on Janux, cranking it nearly 50% higher to $62 per share. What Janux has done, however, is push to extend its runway with a fresh share issue. |
JANX Stock Hits Record High on Prostate Cancer Study DataAn early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC. |
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A RideShares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment. |
Janux Therapeutics Announces Proposed Public OfferingSAN DIEGO, December 03, 2024--Janux Therapeutics Announces Proposed Public Offering |
Sector Update: Health Care Stocks Mixed Late AfternoonHealth care stocks were mixed in late Tuesday afternoon trading with the NYSE Health Care Index addi |
Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market BuzzJanux shares climb 41% in five days, fueled by positive trial results for prostate cancer therapy JANX007 |
Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial ResultsJanux Therapeutics stock surged Tuesday after the company found success during a Phase I trial for a novel prostate cancer treatment. Shares of the California-based biopharmaceutical company climbed 63% to $65.59, snapping a five-day losing streak, after Janux reported promising results during a Phase I clinical trial for JANX007, a treatment for patients with advanced-stage prostate cancer. Higher levels of the protein are generally associated with cancer. |
Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a YearUnprecedented cancer trial results and a $3B sales forecast drive Janux to biotech stardom |